By Fineline Cube 
WuXi Biologics (HKG: 2269) announced its interim results for the six months ended 30 June 2026, reporting revenue of RMB 11.8 billion, up 18.4% year‑on‑year, driven by strong demand for new IND projects, continuous progression of projects into late‑stage development, and growing commercial manufacturing programs. The company achieved positive free cash flow of RMB 1.5 billion in the first half — its fifth consecutive year of positive free cash flow in H1.
2026H1 Financial Highlights
| Metric | 2026H1 | Detail |
|---|---|---|
| Revenue | RMB 11.8B | +18.4% YOY |
| Free Cash Flow | RMB 1.5B | Positive for fifth consecutive year |
| Integrated Projects Added | 169 | 123 organic (+43% YOY) + 46 via WuXi XDC’s acquisition of Tot Biopharm |
| Total Integrated Projects | 1,064 | As of 30 June 2026 |
| Phase III Projects | 78 | Late‑stage pipeline expansion |
| Commercial Manufacturing Projects | 28 | Sustained commercial revenue growth |
Growth Drivers
- Organic Project Momentum: 123 organically grown integrated projects, up 43% YOY, with two‑thirds originating from the U.S. and Europe — highlighting strong demand from major pharmaceutical companies and biotech firms in key Western markets.
- Inorganic Expansion: 46 integrated projects added through WuXi XDC’s acquisition of Tot Biopharm, strengthening the Group’s capabilities in the rapidly growing XDC (antibody‑drug conjugate) segment.
- Late‑Stage and Commercial Mix: The expansion to 78 Phase III projects and 28 commercial manufacturing projects continues to shift the portfolio toward higher‑value, recurring‑revenue manufacturing — a structural tailwind for margins.
Research Business & Royalty Pipeline
- Milestone & Royalty Eligible Projects: More than 50 active projects eligible for milestone payments and sales royalties as of 30 June 2026, laying a foundation for long‑term, high‑margin revenue growth.
- Global Client Base: Over 50% of these projects came from clients outside of China, reflecting the continuous deepening of the Group’s global research services footprint.
Market Impact & Outlook
- Backlog Quality: The record 1,064 integrated projects — with rising Phase III and commercial representation — provides strong visibility into future manufacturing revenue and reinforces WuXi Biologics’ position as a leading global CDMO.
- Geographic Diversification: With two‑thirds of new organic projects sourced from the U.S. and Europe, demand resilience from Western biopharma remains intact despite geopolitical scrutiny of China‑based CRDMOs.
- Cash Generation: Five consecutive years of positive H1 free cash flow underscores the sustainability of the “follow‑the‑molecule” model as projects mature into commercial manufacturing.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding revenue growth, project progression, and commercial manufacturing expectations for WuXi Biologics. Actual results may differ due to risks including client demand, geopolitical developments, and project execution timelines.-Fineline Info & Tech